Q1 EARNINGS: Mixed fortunes for Abbott, St Jude
This article was originally published in Clinica
Abbott’s first-quarter sales of $5.24bn were down 2% year-on-year and fell short of off analyst expectations of $5.28bn, with only its diagnostics subdivision showing any growth. But the firm was hit by unfavorable exchanges rates, with group revenues up 0.5% at constant currency. In addition, diluted earnings of $0.41 per share beat its previous guidance of $0.34-0.36, and came in ahead of analyst consensus of $0.36.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.